Supplementing the R&D portfolio through licensing activities
First written in FY2016. 17 of 21 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-05-21.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「In June this year, the company entered into an exclusive license agreement with US-based Vertex Pharmaceuticals for the development and commercialization in Japan and South Korea of Povetacicept, a treatment for multiple serious B-cell-mediated diseases, including IgA nephropathy and primary membranous nephropathy. In August this year, it entered into a license agreement with SEIKAGAKU CORPORATION for the joint development and exclusive sale in Japan of Gel-One, a treatment for osteoarthritis.」
The company acquired exclusive development and commercialization rights for Povetacicept in Japan and South Korea from Vertex, and also entered into an agreement with SEIKAGAKU CORPORATION for the joint development and exclusive sale of Gel-One. - FY2025AdvancedAnnual report
「In March this year, the company entered into an exclusive worldwide license agreement with US-based Ionis Pharmaceuticals for the development and commercialization of Sapablursen, a treatment for polycythemia vera.」
The company acquired worldwide exclusive rights to Sapablursen from Ionis Pharmaceuticals, giving concrete shape to the supplementation of its R&D portfolio through licensing activities. - FY2025-H1New ADC in-licensing and non-exercise of option rightsAnnual report
「In October this year, we entered into a license agreement with South Korea's LigaChem Biosciences for the antibody-drug conjugate (ADC) LCB97 for solid tumors, as well as a drug discovery partnership agreement for the creation of new ADCs using its ADC platform. In October this year, we decided not to exercise the option under the asset acquisition agreement with exclusive option rights for itolizumab entered into with US-based Equillium in December 2022, for strategic reasons.」
While advancing the ADC licensing and drug-discovery collaboration with LigaChem Biosciences, the company decided not to exercise its exclusive option for Equillium's itolizumab. The expansion and selectivity of its licensing activities are both documented. - FY2024AdvancedAnnual report
「• In March this year, we entered into a license agreement with South Korea's NEX-I concerning the antibody NXI-101 against ONCOKINE-1, a factor associated with resistance to cancer immunotherapy.」
We newly entered into a license agreement with NEX-I concerning NXI-101, advancing the supplementation of the R&D portfolio through external in-licensing. - FY2023-Q3AdvancedAnnual report
「Our company | Equillium | United States | Exclusive option rights related to itolizumab | Development costs | Upfront payment | From December 2022 | Until payment of consideration is completed」
We entered into a technology in-licensing agreement with Equillium in December 2022 to acquire exclusive option rights related to itolizumab, advancing the supplementation of the R&D portfolio through external in-licensing. - FY2023-Q2RestatedAnnual report
「We are also working to in-license promising new drug candidates through licensing activities and further strengthen our R&D activities.」
The policy of in-licensing promising candidate compounds through licensing activities and strengthening R&D has been reaffirmed. - FY2021AdvancedAnnual report
「In October last year, we entered into a license agreement with South Korea's SK Biopharmaceuticals for the exclusive development and commercialization in Japan of its antiepileptic drug Cenobamate. In December last year, we entered into a license agreement with Chordia Therapeutics for the exclusive worldwide development and commercialization of its MALT1 inhibitor CTX-177. In February this year, we entered into a license agreement with US-based Ribon Therapeutics for the exclusive development and commercialization in Japan, South Korea, Taiwan and ASEAN countries of its PARP7 inhibitor RBN-2397.」
The addition of Cenobamate, a MALT1 inhibitor and a PARP7 inhibitor advanced the supplementation of the R&D portfolio through external in-licensing and expanded the regions covered. - FY2021-Q3AdvancedAnnual report
「Our company | Chordia Therapeutics | Japan | Technology related to MALT1 inhibitors | Upfront payment | Royalties | From December 2020 | Until payment of consideration is completed」
We entered into an agreement with Chordia Therapeutics in December 2020 to in-license technology related to MALT1 inhibitors, advancing the supplementation of the R&D portfolio through external in-licensing. - FY2021-Q2AdvancedAnnual report
「In October this year, we entered into a license agreement with South Korea's SK Biopharmaceuticals for the exclusive development and commercialization in Japan of its antiepileptic drug Cenobamate.」
We acquired exclusive development and commercialization rights in Japan for Cenobamate from SK Biopharmaceuticals, advancing the supplementation of the R&D portfolio through external in-licensing. - FY2020-Q2AdvancedAnnual report
「In July this year, we entered into a license agreement with US-based Forty Seven for the exclusive development and commercialization in Japan, South Korea, Taiwan and ASEAN countries of its anti-CD47 antibody 5F9.」
We entered into an agreement to acquire exclusive development and commercialization rights for the anti-CD47 antibody 5F9 in Japan, South Korea, Taiwan and ASEAN countries, advancing the supplementation of the R&D portfolio through external in-licensing. - FY2020-Q1AdvancedAnnual report
「Our company | Rafael | United States | Technology related to CPI-613 (devimistat) | Upfront payment | Royalties | From June 2019 | Until payment of consideration is completed」
We entered into a technology in-licensing agreement with US-based Rafael concerning CPI-613 (devimistat) in June 2019, advancing the supplementation of the R&D portfolio through external technology. - FY2019AdvancedAnnual report
「In January this year, we entered into a license agreement with Canadian company Repare for the exclusive development and commercialization in Japan, South Korea, Taiwan, Hong Kong and Macau (excluding mainland China) and ASEAN countries of its Pol-theta (Polθ) inhibitor.」
A new license agreement has been entered into to acquire exclusive development and commercialization rights for a Polθ inhibitor across a broad region including Asia. - FY2018RestatedAnnual report
「In May last year, we entered into a license agreement with US-based Array for the development and commercialization in Japan and South Korea of the MEK inhibitor ONO-7703/binimetinib and BRAF inhibitor ONO-7702/encorafenib, which Array was developing. In October last year, we entered into a license agreement with US-based Karyopharm for the exclusive development and commercialization of the oral XPO1 inhibitor Selinexor and the second-generation oral XPO1 inhibitor KPT-8602.」
The policy of in-licensing candidate compounds and technologies through external licensing has been reaffirmed through the cumulative agreements reported through the previous quarter. - FY2018-Q2AdvancedAnnual report
「In May this year, we entered into a license agreement with Array for the development and commercialization in Japan and South Korea of the MEK inhibitor Binimetinib and the BRAF inhibitor Encorafenib, which Array is developing. In September this year, we entered into an agreement with 生化学工業 for the joint development and marketing partnership in Japan of SI-613, a treatment for osteoarthritis under development by the company. In September this year, we entered into a development partnership agreement with Eisai Co.,Ltd. concerning combination therapy for hepatocellular carcinoma involving Opdivo and Eisai Co.,Ltd.'s Lenvima. In October this year, we entered into a license agreement with Karyopharm for the exclusive development and commercialization in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries of the first-in-class oral XPO1 inhibitor Selinexor and the second-generation oral XPO1 inhibitor KPT-8602, for all cancer types.」
We entered into licensing, joint development and development partnership agreements with Array, 生化学工業, Eisai Co.,Ltd. and Karyopharm, advancing the supplementation of the R&D portfolio through external in-licensing. - FY2018-Q1AdvancedAnnual report
「Our company | Array | United States | Technology related to encorafenib and binimetinib | Upfront payment | Royalties | From May 2017 | Until payment of consideration is completed」
We entered into a technology in-licensing agreement with Array concerning encorafenib and binimetinib in May 2017, adding external in-licensing for consideration consisting of an upfront payment and royalties. - FY2017AdvancedAnnual report
「In December last year, we entered into a license agreement with Ligand to acquire rights to create fully human monospecific or bispecific antibodies using its genetically modified animals OmniRat®, OmniMouse® and OmniFlic®.」
We entered into a license agreement with Ligand to acquire rights to its fully human antibody-generation technology, advancing the supplementation of the R&D portfolio through external technology in-licensing. - FY2017-Q2AdvancedAnnual report
「In May this year, we entered into an option agreement with IDAC セラノスティクス株式会社 (IDAC) to give us priority evaluation and licensing negotiation rights for the humanized anti-CD4 antibody IT1208, which IDAC is developing for pharmaceutical use in cancer. In July this year, we acquired exclusive rights to develop and commercialize NKR-2, an allogeneic CAR-T cell therapy using the natural killer cell receptor NKG2D, which Celyad is developing for cancer in Europe and the United States, in Japan, South Korea and Taiwan.」
External in-licensing activities have made concrete progress through the option agreement for licensing negotiations on IT1208 and the acquisition of exclusive development and commercialization rights for NKR-2 in Japan, South Korea and Taiwan. - FY2017-Q1AdvancedAnnual report
「The proteasome inhibitor Kyprolis intravenous infusion obtained marketing approval in Japan for the indication of relapsed or refractory multiple myeloma.」
Kyprolis, listed in the development portfolio as an in-licensed product from Onyx, has made concrete post-licensing progress through the acquisition of marketing approval in Japan. - FY2016First statedAnnual report
「Going forward, in addition to aiming to create original and groundbreaking pharmaceuticals using world-leading technologies in Japan and overseas, we will work to introduce promising compounds through licensing activities and further strengthen our R&D activities.」
The company positions the in-licensing of promising compounds through external licensing as an ongoing means of strengthening R&D.